Efficacy and toxicity of stereotactic radiotherapy combined with third-generation EGFR-TKIs and immunotherapy in patients with brain metastases from non-small cell lung cancer

Strahlentherapie und Onkologie, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 26, 2025

Stereotactic radiotherapy (SRT) is fast gaining attention as a preferred treatment alternative for patients with brain metastases (BM) from non-small cell lung cancer (NSCLC). In this study, we examined the efficacy and safety of combining SRT immunotherapy (IT) targeted therapy (TT), either separately or concurrently aim to formulate an optimal therapeutic regimen NSCLC BM. The combination were comprised IT TT agents. For SRT-combined agents group, was limited third-generation EGFR-TKIs. administration these drugs within 30 days before after defined therapy. primary endpoint 1-year progression-free survival (PFS), which evaluated by blinded independent review committee categorized into local recurrence at radiation site emergence new distant intracranial metastases. Secondary endpoints included confirmed objective response rate (IORR) disease control in overall population. Post-treatment grading performed according CTCAE, levels necrosis differentiated. 266 BM following four groups based on their methods: alone, combined IT, EGFR-TKIs, both TT. range, 1‑year PFS 77.89% (P = 0.239), 88.75% 0.266), 88.01% 0.210), 91.97% 0.057), respectively. outside site, corresponding values 63.96% 0.039), 74.17% 0.258), 88.70% 0.024), 87.81% 0.015), By end study period, IORR increased 32% alone 46% 58% 61% groups. However, group that received exhibited higher occurrence grade 3 adverse events, statistically significant difference observed necrosis. BM, TT, together tumor control. Nonetheless, acute events. Thus, while provided good independently, incidence symptomatic RN low.

Language: Английский

Hippocampal microstructural changes following electroconvulsive therapy in severe depression

Molecular Psychiatry, Journal Year: 2025, Volume and Issue: unknown

Published: April 8, 2025

Language: Английский